Shocking research on epidemics: AB, B blood group members, and carnivores need to be more stable than corona, O blood group impact less

The Council of Scientific and Industrial Research (CSIR) has released a research paper, which has revealed some shocking facts related to the epidemic. According to this research, people from AB and B blood groups need to be more stable than Covid-19. People with O blood group have the least impact of the disease. Most patients in this blood group are either asymptomatic or have very mild symptoms.

This report has been prepared based on data from a seropositive survey. It has taken data from 10,000 people in the country and analyzed it by a team of 140 doctors. The report said that non-vegetarians are more prone to coronavirus infection than vegetarians.

3 expert comments on the survey

Talking to a news channel on this survey, Agra pathologist Dr. Ashok Sharma said that everything depends on the genetic structure of a person.

For example, a person suffering from Thalassemia rarely has malaria. There are many examples in which the whole family got an infection, but one person from the same family survived it. The reason is the genetic structure.

Dr. Sharma said that it may be that the immune system of the O blood group is stronger than the AB and B groups against this virus. However, more research needs to be done on this research right now. However, this research does not mean that people with O blood groups should stop following the Covid protocol. They are not completely immune to this virus and they may also face problems.

Senior Physician Dr. SK Kalra said that this is only a sample survey. These are not research papers reviewed by experts. In this, it is not clear on a scientific basis why the infection rates of different blood groups are different. Right now it is too early to connect O blood group and better immunity.

Indian vaccine trial now on children

If everything goes well, soon after Canada and America, Corona's indigenous vaccine will be ready for the age group of 2 to 18 years in India too. The Subject Experts Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) on Tuesday approved second and third trials of covaxin of Bharat Biotech on ages 2 to 18, according to the news agency. The trial will be conducted on 525 subjects at AIIMS Delhi, AIIMS Patna, and Meditrina Institute of Medical Sciences Nagpur. The Subject Experts Committee on Tuesday considered the proposal of Bharat Biotech in Hyderabad.

Corona epidemic statistics in the country

Total new cases came in last 24 hours: 3.48 lakh

Total deaths in last 24 hours: 4,198

Total recovered in last 24 hours: 3.55 lakhs

Total infected so far: 2.33 crore

Till now healed: 1.93 Crore

Total deaths so far: 2.54 lakh

Total number of patients currently undergoing treatment: 36.99 Lakh